Pipeline Overview

We are developing a pipeline of next-generation therapies designed to be highly potent, selective, and CNS-permeable. We are focused on targeting well-validated cancer drivers which have difficult, unsolved medicinal chemistry challenges.

Early Preclinical
Candidate Selection
Phase 1
RL212
Advanced melanoma
KRAS-mutant PDAC
RL055
Metastatic breast cancer
Primary brain tumors
RL316
Hematologic malignancies
Primary brain tumors
Neuroblastoma
Discovery